European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-05-27

NOX enzymes as mediators of inflammation-triggered neurodegeneration: modulating NOX enzymes as novel therapies

Objectif

NEURINOX aims at elucidating the role of NADPH oxidases (NOX) in neuroinflammation and its progression to neurodegenerative diseases (ND), as well as evaluating the potential of novel ND therapeutics approaches targeting NOX activity. NOX generate reactive oxygen species (ROS) and have emerged as regulators of neuroinflammation. Their role is complex: ROS generated by NOX lead to tissue damage in microglia-mediated neuroinflammation, as seen in amyotrophic lateral sclerosis (ALS), while absence of ROS generation enhances the severity of autoimmune-mediated neuroinflammation, as seen for e.g. in multiple sclerosis (MS).
The objective of the 5 years NEURINOX project is to understand how NOX controls neuroinflammation, identify novel molecular pathways and oxidative biomarkers involved in NOX-dependent neuroinflammation, and develop specific therapies based on NOX modulation. The scientific approach will be to: (i) identify NOX-dependent molecular mechanisms using dedicated ND animal models (ii) develop therapeutic small molecules either inhibiting or activating NOX and test their effects in animal models (iii) test the validity of identified molecular pathways in clinical studies in ALS and MS patients.
NEURINOX will contribute to better understand brain dysfunction, and more particularly the link between neuroinflammation and ND and to identify new therapeutic targets for ND. A successful demonstration of the benefits of NOX modulating drugs in ALS and MS animal models, and in ALS early clinical trials will validate a novel high potential therapeutics target for ALS and also many types of ND. NEURINOX has hence a strong potential for more efficient ND healthcare for patients and thus for reducing ND healthcare costs.
This multi-disciplinary consortium includes leading scientists in NOX research, ROS biology, drug development SMEs, experts in the neuroinflammatory aspects of ND, genomics and proteomics, and clinicians able to translate the basic science to the patient.

Champ scientifique

Programme(s)

Thème(s)

Appel à propositions

FP7-HEALTH-2011-two-stage
Voir d’autres projets de cet appel

Régime de financement

CP-IP - Large-scale integrating project

Coordinateur

UNIVERSITE DE GENEVE
Contribution de l’UE
€ 1 493 755,95
Adresse
RUE DU GENERAL DUFOUR 24
1211 Geneve
Suisse

Voir sur la carte
Région
Schweiz/Suisse/Svizzera Région lémanique Genève
Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Karl-Heinz Krause (Prof.)
Liens
Coût total
Aucune donnée

Participants (14)

Partager cette page

Télécharger

Dernière mise à jour: 16 Janvier 2017

Mon livret

Permalink: https://cordis.europa.eu/project/id/278611/fr

European Union, 2024